TD Cowen reiterates Buy rating on Senseonics Holdings, $15 price target

What happened

TD Cowen repeated its Buy rating on Senseonics Holdings stock with a $15.00 price target. That target implies an upside of 100.5% from the October 26 close of $7.48. Senseonics has also begun first-in-human testing of its next-generation FREEDOM CGM platform.

Confirmed

Global impact / market context

A repeat Buy rating with a target well above the last close signals that TD Cowen sees room for the stock to rise. The FREEDOM platform aims to remove the external transmitter, which could make the product easier to use and help Senseonics win more diabetes patients.

Analyst inference

Senseonics competes in the growing continuous glucose monitoring market, where ease of use helps attract patients. TD Cowen points to upcoming FREEDOM and GEMINI launches plus the existing Eversense 365 as growth drivers. Higher product sales would raise revenue and could support more spending on development.

Analyst inference

What to watch

1. Watch first-in-human testing progress for the FREEDOM platform, which aims to remove the external transmitter. Encouraging preclinical results were cited in the analyst note as support for the technical feasibility of this approach. Confirmed
2. Track the upcoming launches of FREEDOM and GEMINI alongside Eversense 365. TD Cowen frames this roadmap as a possible driver of revenue growth and wider patient reach, so launch timing and adoption matter. Proposed
3. Watch whether sales growth funds continued product development and whether the stock moves toward the $15.00 target from the $7.48 close. Slower adoption would weaken the case for the Buy rating and its implied upside. Analyst inference

Evidence

• Original source link unavailable